Daniel Gomez
Chair, Radiation Oncology
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (60)
Supplementary Figure 21. (A) Intratumoral, (B) tumor-stroma interface, and (C) total CD8+ PD1+ T cells in ATMMUT and ATMWT NSCLCs. (D) Intratumoral, (E) tumor-stroma interface, and (F) total FOXP3+ immune cells in ATMMUT and ATMWT NSCLCs.
Year:
2025
Supplementary Figure 14. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with advanced/metastatic PD-L1 negative (
Year:
2025
Supplementary Figure 7. (A) Histograms showing the distribution of deleterious class I and class II ATM mutations with lost or intact ATM protein expression by IHC. (B) Histograms showing the distribution of deleterious missense, nonsense, splice site, and insertion/deletion mutations with lost or intact ATM protein expression by IHC. (C) proportion of NSCLCs with predicted benign and predicted pathogenic ATM missense mutations with lost and intact ATM expression by IHC.
Year:
2025
Supplementary Figure 29. Box plot showing immune cell subsets significantly enriched among ATMMUT versus ATMWT NSCLC as assessed by deconvoluting bulky RNAseq data from the TCGA-NSCLC dataset. Non-significant results are not shown.
Year:
2025
Supplementary Figure 19. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with ATMMUT NSCLC, according to KEAP1 mutation. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with ATMMUT NSCLC, according to KEAP1 mutation status
Year:
2025
Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received concurrent chemoradiotherapy followed by durvalumab maintenance according to ATM mutation status.
Year:
2025
Supplementary Figure 5. (A) Median distance of each missense mutation from the closest intron start. (B) Median distance of each missense mutation from the closest intron end. (C) Proportion of cases with ATM loss and ATM intact expression by IHC in NSCLC samples with ATM mutation and ATM loss-of-heterozygosity (LOH).
Year:
2025
Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.
Year:
2025
Supplementary Figure 16. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition monotherapy among patients with advanced/metastatic NSCLC, according to ATM/TP53 co-mutation status. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 inhibition in combination with chemotherapy among patients with advanced NSCLC, according to ATM/TP53 co-mutation status.
Year:
2025
Supplementary Figure 28. (A) Box-plot showing the distribution of tumor-infiltrating lymphocytes assessed using computational pathology algorithm in ATMMUT and ATMWT NSCLCs. (B) Box-plot showing the distribution of tumor-infiltrating lymphocytes assessed using computational pathology algorithm in according to ATM/TP53 co-mutation status in NSCLC.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (9)
Alessandro Di Federico
University of Bologna
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Hersh Gupta
Dana-Farber Cancer Institute
Mizuki Nishino
King’s College London
Andreas de Biasi
Assistant Professor
University of Wisconsin-Madison
Andrew D Cherniack
Group Leader
Dana-Farber Cancer Institute
Scott Rodig
Professor of Pathology
Beth Israel Deaconess Medical Center
Matthew Skovgard
Thoracic Surgeon, Assistant Professor of Clinical Surgery
University of California, San Francisco
vivek mittal
Professor/Director
Weill Cornell Medicine
Make your next move.
Prepare your application
Review drafts before you send them.